INT255074

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.22
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLP1R) plasma membrane (GLP1R) signal transducer activity (GLP1R)
GLP1R (Homo sapiens)
Pain Link Frequency Relevance Heat
potassium channel 2 7.60 Low Low
Neuropeptide 4 5.00 Very Low Very Low Very Low
adenocard 2 5.00 Very Low Very Low Very Low
chemokine 2 5.00 Very Low Very Low Very Low
cytokine 1 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
withdrawal 1 5.00 Very Low Very Low Very Low
Inflammation 1 5.00 Very Low Very Low Very Low
abdominal pain 1 5.00 Very Low Very Low Very Low
agonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 57 92.04 High High
Hypoglycemia 4 58.60 Quite High
Apoptosis 1 47.04 Quite Low
Obesity 5 23.40 Low Low
Disease 6 5.00 Very Low Very Low Very Low
Hyperglycemia 5 5.00 Very Low Very Low Very Low
Infection 5 5.00 Very Low Very Low Very Low
Insulin Resistance 5 5.00 Very Low Very Low Very Low
Body Weight 4 5.00 Very Low Very Low Very Low
Cardiovascular Disease 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The strategy of inhibiting DPP-4 is to prevent the inactivation of GLP-1 and therefore to enhance and prolong the effects of the endogenously released incretin hormone.
Negative_regulation (prevent) of Negative_regulation (inactivation) of GLP-1
1) Confidence 0.27 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.22 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox